Study of REGN5458 plus Carfilzomib for multiple myeloma.

Trial ID:
IRB-23-8272
Anuj Mahindra, MD

Inclusion Criteria

Patients must:

  • Have an ECOG status of less than/or equal to 1.
    Have relapsed/refractory multiple myeloma with progression.
    Have measurable disease according to IMWG criteria.
    Have adequate creatinine clearance, hematology function, and hepatic function.
    Have a life expectancy of at least 6 months.

Exclusion Criteria

Patients must not:

  • Have a diagnosis of plasma cell leukemia, primary light-chain amyloidosis, Waldestrom macroglobulinemia, or POEMS syndrome.
    Have multiple myeloma brain lesions or meningeal involvement.
    Have prior treatment with any systemic anti-myeloma therapy without proper washout or within 21 days before administration of the study drug (whichever is shorter).
    Have a history of allogeneic or autologous stem cell transplantation within 12 weeks before administration of the study drug.
    Have a History of progressive multifocal leukoencephalopathy neurodegenerative condition, central nervous system (CNS) movement disorder, and history of seizures within 12 months before study enrollment.
    Have a live or attenuated vaccine within 28 days before the first study drug administration.

Additional Info

* A bone marrow aspirate and biopsy (BMBX) may be required during the screening period (depending on when your last BMBX was performed and if any samples are left over for research testing).

* All treatments and physician visits during this study will occur at Scripps Clinic Torrey Pines (Geisel Pavilion) or Scripps Green Hospital.

* Search NCT05137054 at https://clinicaltrials.gov website for more information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org